365 related articles for article (PubMed ID: 34310025)
1. Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
Sancho M; Leiva D; Lucendo E; Orzáez M
FEBS J; 2022 Oct; 289(20):6209-6234. PubMed ID: 34310025
[TBL] [Abstract][Full Text] [Related]
2. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
Dunham D; Viswanathan P; Gill J; Manzano M
J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
[TBL] [Abstract][Full Text] [Related]
3. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
Voutsadakis IA
Gene; 2022 Dec; 847():146881. PubMed ID: 36100115
[TBL] [Abstract][Full Text] [Related]
5. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.
Okamoto T; Coultas L; Metcalf D; van Delft MF; Glaser SP; Takiguchi M; Strasser A; Bouillet P; Adams JM; Huang DC
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):261-6. PubMed ID: 24363325
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
7. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
[TBL] [Abstract][Full Text] [Related]
8. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation.
Arai S; Varkaris A; Nouri M; Chen S; Xie L; Balk SP
Elife; 2020 Jun; 9():. PubMed ID: 32484436
[TBL] [Abstract][Full Text] [Related]
9. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
10. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells.
Chiou JT; Lee YC; Wang LJ; Chang LS
Chem Biol Interact; 2022 Jul; 361():109978. PubMed ID: 35561756
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
[TBL] [Abstract][Full Text] [Related]
12. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
[No Abstract] [Full Text] [Related]
13. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
14. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
Chiou JT; Wu YY; Lee YC; Chang LS
Biochem Pharmacol; 2023 Sep; 215():115738. PubMed ID: 37562509
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
16. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
17. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
18. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
[TBL] [Abstract][Full Text] [Related]
19. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.
Klanova M; Kazantsev D; Pokorna E; Zikmund T; Karolova J; Behounek M; Renesova N; Sovilj D; Kelemen CD; Helman K; Jaksa R; Havranek O; Andera L; Trneny M; Klener P
Mol Cancer Ther; 2022 Jan; 21(1):89-99. PubMed ID: 34728569
[TBL] [Abstract][Full Text] [Related]
20. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
